Unicycive Therapeutics, Inc. (UNCY) Key Metrics
UNCY valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $92.0M
- Enterprise value
- $73.6M
- P/E (TTM)
- —
- Forward P/E
- 1.5
- PEG ratio
- —
- Price / sales
- 23.8
- Price / book
- 2.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.82
UNCY key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsUNCY valuation Price multiples at each fiscal year-end price.
UNCY returns How much profit the business earns on the capital it uses.
UNCY per-share figures Results divided by the shares outstanding at year-end.
UNCY financial health Debt, liquidity and how easily interest is covered.
UNCY efficiency & capital use Working capital cycle and where the cash goes.
UNCY valuation history
UNCY returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
UNCY debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
UNCY cash returned to shareholders
UNCY price vs earnings per share
UNCY key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $91.7M | $53.2M | — | — | — | — | — | — |
| Enterprise value | $50.6M | $27.8M | — | — | — | — | — | — |
| Price / book | 3.0 | 7.2 | — | — | — | — | — | — |
| Earnings yield | −29.0% | −69.1% | — | — | — | — | — | — |
| Free cash flow yield | −34.2% | −53.9% | — | — | — | — | — | — |
| Dividend yield | 0.0% | 2.1% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 2.1% | — | — | — | — | — | — |
| Share price at fiscal year-end | $5.77 | $7.94 | $8.68 | $5.40 | $20.60 | — | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$1.67 | −$5.48 | — | — | — | — | — | — |
| Operating cash flow per share | −$1.97 | −$4.27 | — | — | — | — | — | — |
| Free cash flow per share | −$1.97 | −$4.28 | — | — | — | — | — | — |
| Cash per share | $2.60 | $3.90 | — | — | — | — | — | — |
| Book value per share | $1.90 | $1.11 | — | — | — | — | — | — |
| Tangible book value per share | $1.90 | $1.11 | — | — | — | — | — | — |
| Dividends per share | $0.00 | $0.16 | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.01 | — | — | — | — | — | — |
| Debt per share | $0.01 | $0.12 | — | — | — | — | — | — |
| Shares outstanding | 15.9M | 6.7M | — | — | — | — | — | — |
| Change in shares outstanding | +137.2% | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −141.1% | — | — | — | −153.9% | — | — | — |
| Return on assets (ROA) | −65.7% | −160.2% | −359.2% | −167.6% | −112.2% | — | — | — |
| Return on tangible assets | −54.0% | −116.0% | −215.2% | −641.0% | −56.7% | — | — | — |
| Financial health | ||||||||
| Total debt | $199,000 | $773,000 | $811,000 | $201,000 | $335,000 | $2.5M | $460,000 | $1.0M |
| Cash & short-term investments | $41.3M | $26.1M | $9.7M | $455,000 | $16.6M | — | $15,000 | $25,000 |
| Net debt | −$41.1M | −$25.4M | −$8.9M | −$254,000 | −$16.2M | $2.5M | $445,000 | $1.0M |
| Debt / equity | 0.01 | 0.10 | — | — | 0.02 | — | — | — |
| Debt / assets | 0.00 | 0.02 | 0.06 | 0.07 | 0.02 | 12.32 | 24.21 | 36.10 |
| Current ratio | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 | 0.02 | 0.02 |
| Quick ratio | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 | 0.02 | 0.02 |
| Interest coverage | -415.7 | -452.4 | -253.3 | — | -14.3 | -8.3 | -14.1 | — |
| Working capital | $30.0M | $6.8M | −$4.1M | −$640,000 | $16.3M | −$2.7M | −$884,000 | −$1.2M |
| Invested capital | −$10.9M | −$17.9M | −$12.7M | −$720,000 | $240,000 | −$157,000 | −$439,000 | −$184,000 |
| Tangible asset value | $30.2M | $7.4M | −$3.8M | −$466,000 | $16.5M | −$2.7M | −$884,000 | −$1.2M |
| Net current asset value | $30.0M | $6.7M | −$4.6M | −$640,000 | $16.2M | −$2.7M | −$884,000 | −$1.2M |
| Graham net-net per share | $1.41 | $0.28 | — | — | — | — | — | — |
| Capital allocation | ||||||||
| Dividends paid | $0 | $1.1M | $867,000 | — | — | — | — | — |
| Capex / revenue | — | — | 1.8% | 0.2% | — | — | — | — |
| Capex / depreciation | 0.04 | 0.17 | 0.04 | 0.01 | 2.23 | 0.01 | 0.01 | 0.03 |
| Stock-based compensation / revenue | — | — | 261.8% | 110.1% | — | — | — | — |
| R&D / revenue | — | — | 1,911.4% | 1,307.7% | — | — | — | — |
| SG&A / revenue | — | — | 1,308.3% | 690.5% | — | — | — | — |
| Efficiency | ||||||||
| Days payables outstanding | 404.2 | 762.0 | 1,071.2 | 41,401.4 | 168,995.0 | — | — | — |
| Payables turnover | 0.90 | 0.48 | 0.34 | 0.01 | 0.00 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.08 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $633,500 | $893,500 | $833,500 | $794,000 | $463,000 | $253,000 | $191,000 | $60,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from UNCY's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
UNCY valuation and financial ratios
Unicycive Therapeutics earned a return on equity of −141.1% in fiscal 2025. It ended the year with $0.2 million of debt and $41.3 million in cash and short-term investments, a net cash position of $41.1 million.
See the UNCY income statement, the UNCY chart for price history, or the UNCY stock overview for the latest quote and news.
UNCY key metrics FAQ
What is Unicycive Therapeutics's return on equity?
Unicycive Therapeutics's return on equity (ROE) was −141.1% in fiscal 2025: net income of -$26.6 million on average shareholders' equity of $18.8 million.
How much debt does Unicycive Therapeutics have?
Unicycive Therapeutics had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
Does Unicycive Therapeutics pay a dividend?
Unicycive Therapeutics did not pay a dividend in fiscal 2025.
What is Unicycive Therapeutics's free cash flow yield?
Unicycive Therapeutics generated -$31.3 million of free cash flow in fiscal 2025, a free cash flow yield of −34.2% on its market value at year-end ($91.7 million).
What is Unicycive Therapeutics's current ratio?
Unicycive Therapeutics's current ratio was 2.59 at the end of fiscal 2025: current assets were 2.59 times current liabilities.